Elicio Therapeutics, Inc. (ELTX) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Elicio Therapeutics, Inc. (ELTX) closed at USD 1.79 on 2026-10-14, a change of -81.6 % over the past year, with a market capitalization of USD 48.22M.

Elicio Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Elicio Therapeutics, Inc. key figures

Previous close

USD 1.79 (2026-10-14)

1-year change

-81.6 %

Market cap

USD 48.22M

Enterprise value

USD 37.45M

P/E ratio (trailing)

-0.82

P/E ratio (forward)

-1.05

EPS (trailing)

-2.16

EPS (forward)

-1.69

PEG ratio

n/a

Price to book

4.92

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

4.07

Employees

33

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Elicio Therapeutics, Inc.

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targeted AMP peptide vaccine in preclinical studies for the treatment of mutated tumor protein p53-expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Elicio Therapeutics, Inc. and compare it with other stocks.